Heyman Richard A. sold $45K of ORIC
Heyman Richard A. sold 3,500 shares of Oric Pharmaceuticals, Inc. (ORIC) at $12.91 on 2026-10-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest and unlikely to move the stock significantly, but it provides transparency for investors.
Market read
A routine insider sale with limited market impact; useful for compliance monitoring.
What to watch
Potential tax planning or diversification motives behind the 10b5-1 sale.
Background
Form 4 filings disclose insider transactions and are primary sources for such events.
Ticker impact
Director Richard Heyman sold 3,500 shares for $45,199 via a 10b5-1 plan, reducing his stake to 38,300 shares.
likely slight downward pressure as the market prices in the insider sale
The sale is small relative to market cap and disclosed via a Form 4, indicating a routine transaction with limited impact.
Market effects
None significant for the biotech sector.
No regional effect.
Limited to ORIC shareholders.
Counterpoint
The sale could be a signal of upcoming negative news, warranting a short position.
Key entities
- CompanyOric Pharmaceuticals, Inc.
Biotech company listed on NASDAQ under ticker ORIC.
- IndividualRichard A. Heyman
Director of Oric Pharmaceuticals who sold shares.
